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Abstract
Background: In the treatment of PTSD, meta-analyses suggest comparable efficacy of cognitive behavioural therapies
and various trauma focused treatments, but results for other treatments are inconsistent. One meta-analysis found no
differences for bona fide therapies, but was critizised for overgeneralization and a biased study sample and relied on an
omnibus test of overall effect size heterogeneity that is not widely used.
Methods: We present an updated meta-analysis on bona fide psychotherapies for PTSD, contrasting an improved
application of the omnibus test of overall effect size heterogeneity with conventional random-effects meta-analyses of
specified treatment types against all others. Twenty-two studies were eligible, reporting 24 head-to-head comparisons
in randomized controlled trials of 1694 patients.
Results: Head-to-head comparison between trauma focused and non-trauma focused treatments revealed a small
relative advantage for trauma focused treatments at post-treatment (Hedges’ g = 0.14) and at two follow-ups
(g = 0.17, g = 0.23) regarding PTSD symptom severity. Controlling and adjusting for influential studies and publication
bias, prolonged exposure and exposure therapies (g = 0.19) were slightly more efficacious than other therapies
regarding PTSD symptom severity at post-treatment; prolonged exposure had also higher recovery rates (RR = 1.26).
Present-centered therapies were slightly less efficacious regarding symptom severity at post-treatment (g = −0.20) and
at follow-up (g = −0.17), but equally efficacious as available comparison treatments with regards to secondary outcomes.
The improved omnibus test confirmed overall effect size heterogeneity.
Conclusions: Trauma focused treatments, prolonged exposure and exposure therapies were slightly more efficacious
than other therapies in the treatment of PTSD. However, treatment differences were at most small and far below
proposed thresholds of clinically meaningful differences. Previous null findings may have stemmed from not
clearly differentiating primary and secondary outcomes, but also from a specific use of the omnibus test of overall
effect size heterogeneity that appears to be prone to error. However, more high-quality studies using ITT analyses are
still needed to draw firm conclusions. Moreover, the PTSD treatment field may need to move beyond a focus primarily
on efficacy so as to address other important issues such as public health issues and the requirements of highly
vulnerable populations.
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Background
There is an on-going debate on whether psychotherapies
differ in efficacy in the treatment of post-traumatic stress
disorder (PTSD). In the broader context of psychotherapy
research this is a well-known topic since Rosenzweig [1]
introduced the assumption that all psychotherapies are
equally effective because of underlying common factors.
This topic still remains mostly controversial and unsolved
[2], but most notably owing to progress in meta-analytical
methodology, some important contributions from an
evidence-based point of view could be made for which
methodological aspects appeared crucial as well. Whereas
early extensive meta-analyses did not make precise
distinctions between disorders and outcomes [3, 4], but
included different psychotherapies for different disorders,
critics warned against overgeneralization, undifferentiated
methodology, and confounded results [5–8]. Empirical
justification for this critique was provided, for example, in
the treatment of anxiety disorders: there, an advantage
of cognitive behavioural therapy (CBT) over relaxation
treatment pertained in panic disorder but not generalized
anxiety disorder, and was evident in primary, symptom-
oriented, outcomes, but not in secondary, more general,
outcomes [9, 10].
With regards to PTSD, existent meta-analytical re-
views suggest that CBT, trauma focused CBT (TFCBT),
exposure therapies, and eye movement desensitization
reprocessing (EMDR) are equally effective, but results of
non-trauma focused therapies like hypnotherapy, psy-
chodynamic therapy or supportive therapy are heteroge-
neous and inconsistent, meaning either that they are less
effective or were yet not sufficiently examined to prove
their efficacy [11–21]. Especially the status of supportive
therapies appears currently unclear, leaving the question
open whether specific techniques really make any difference
over common factors [10, 22].
Meta-analytical evidence presented by Benish, Imel, and
Wampold [23] fuelled this debate, indicating that any
differences in efficacy of psychotherapies for PTSD vanish
once the analysis is restricted to head-to-head compari-
sons, thus controlling for some possible confounders, like
differences in diagnostic criteria or length of treatment
[8], and includes only ‘bona fide’ psychotherapies, i.e.,
treatments that are intended to be therapeutic. Bona fide
criteria (see the section on Eligibility below) were uti-
lized by this research group also in a number of other
meta-analyses [24–26], but were utilized since by some
independent other researchers as well [22, 27, 28]. The
intention of using bona fide criteria is to restrict the
analysis to head-to-head comparisons of active treat-
ments to raise its validity. Including studies with mere
‘intent-to-fail’ control conditions introduces heterogeneity
and bias, which may result in spurious differences of
treatment efficacy in meta-analysis [23, 29].
The Benish et al. [23] meta-analysis has been criti-
zised for a biased selection of the available evidence
and overgeneralization [30]. For example, Cloitre [31]
included 44 comparisons from 27 studies, whereas Benish
et al. [23] included only 17 comparisons from 15 studies.
Specifically, Benish et al. [23] were critizised for including
present-centered therapies and therapies whose efficacy
appeared debatable, but excluding supportive therapies
[30]. Moreover, supportive therapies have been catego-
rized in other meta-analyses either as active treatments
[12, 32] or mere control conditions [13, 16]. Application
of an operational definition of what constitutes an ‘active
treatment’ is therefore needed (e.g., the bona fide criteria),
in order to make sense of differing results and conclusions
reached by extant reviews and meta-analyses.
However, as of yet, there have been no comprehensive
attempts to update and re-evaluate these issues and results
empirically. One further meta-analysis [19] examined group
treatments for PTSD and found no indication of differences
in treatment efficacy; however, this result was based on a
sample of ten studies wherein treatments were not neces-
sarily bona fide. Ougrin [15] found no differences between
cognitive therapy and exposure therapy, aggregating the
evidence of only five studies. Munder et al. [33] examined
differences between various trauma focused treatments, but
only with regards to their dependency on researcher alle-
giance. Watts et al. [21] presented a comprehensive meta-
analysis on the efficacy of treatments for PTSD, including
also pharmacotherapies, but did not strictly rely on head-
to-head comparisons and psychotherapies were not specifi-
cally bona fide. Tolin [22], focusing specifically on CBT,
reported an advantage of CBT over other psychotherapies
in the treatment of anxiety and depressive disorders, but
not for PTSD. A recently published meta-analysis [14], that
was not restricted to head-to-head comparisons, reported
for adult survivors of childhood abuse best effects for
trauma focused treatments in an individual setting. There-
fore, the studies conducted in this area have been mixed in
their findings and fairly heterogeneous in their approach.
There is yet one further important aspect of the Benish et
al. [23] meta-analysis that did not receive a re-evaluation.
Benish et al. [23] used a specific method (see Methods)
which was proposed by Wampold et al. [4] in order to
circumvent the need for a priori treatment categoriza-
tions. Instead of meta-analytically comparing individual
classes of treatment against all others, as in other meta-
analyses on relative efficacy, Wampold et al. [4] proposed
an omnibus test of overall effect size heterogeneity that
does not rely on a priori treatment categorizations, but on
the random assignment of positive (+) or negative signs
(−) to the effect sizes of the head-to-head comparisons.
The results of the first meta-analysis which used this ap-
proach [4] had a huge impact on the debate on whether
psychotherapies really differ in efficacy. However, this test
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cannot be considered a standard procedure, because it is
not commonly used in meta-analytical research on relative
efficacy. In fact, it seems that it is used only in meta-
analyses of the same researchgroup [4, 23–25, 33]. There-
fore, it remains currently unclear whether this method
provides results that are consistent with conventional
methods. Specifically, low statistical power and the risk of
capitalizing on chance may threaten the statistical conclu-
sion validity of this test (see Methods).
The main aim of this meta-analysis was to make a
contribution to both the overall field of research on rela-
tive treatment efficacy with regards to methodology, and
to the specific field of research on the relative efficacy of
treatments for PTSD, utilizing advanced meta-analytical
methodology. The current study re-addressed the ques-
tion whether there are no differences in the efficacy of
treatments for PTSD, utilizing the bona fide criteria for
an operational definition of ‘active treatments’, updating
the available evidence, and evaluating the study selection
and methodology used by Benish et al. [23] (see Methods
section). Specifically, we improved the application of the
proposed statistical method and contrasted its results with
conventional meta-analysis of direct comparisons, and
also explored whether trauma focused treatments were in
direct head-to-head comparisons more efficacious than
treatments that were non-trauma focused. Moreover, we
also investigated effects of patient and treatment variables
on relative efficacy and controlled for study quality.
Methods
The methodology of this study adhered to PRISMA
guidelines.
Eligibility
Eligibility criteria for studies to be included in this meta-
analysis were (see [23]): (1) a randomized and controlled
study design (RCT), investigating the relative efficacy of
(2) at least two bona fide psychotherapies; (3) therapies
needed to be conducted in two or more sessions; (4)
participants were adults that were (5) diagnosed with
PTSD according to the valid edition of the DSM at the
time of the respective study (DSM-III or DSM-IV); (6)
PTSD symptom severity was assessed with self-report or
clinician rating. Studies that provided insufficient infor-
mation to compute effect sizes were excluded as were
component, dismantling, and parameter studies. More-
over, we also excluded studies that contained mere
additional analyses on previously published data, en-
suring that primary data entered analysis only once.
Target group, treatment format and study quality did
not serve as eligibility criteria in the present study. In
order to examine the possible effect of various patient
and treatment characteristics as well as the influence
of study quality, moderator analyses were conducted
(see the section on Additional Analyses, below). Taylor
and Harvey [32] examined the effects of psychotherapy
specifically for people who have been sexually assaulted
and Ehring et al. [14] for adult survivors of childhood
abuse. Sloan et al. [19] and Bisson et al. [12] examined,
amongst others, group therapies. However, other meta-
analyses did not limit themselves to specific target groups
or treatment formats [13, 16–18, 20, 34].
To qualify as an ‘active treatment’, the bona fide definition
[23, 29] required that treatments had to be delivered by a
trained therapist who adapted the treatment to patients on
the basis of a therapeutic relationship (i.e., no delivery of a
non-modifiable standard protocol, e.g., progressive muscle
relaxation); treatments also needed to be conducted per-
sonally and face-to-face (i.e., no online treatments or treat-
ments conducted with, e.g., audio material). Moreover, at
least two of the following four criteria had to be fulfilled
with regards to their descriptions in the studies: (a) a
citation to an established school or approach to psycho-
therapy; (b) a description of the therapy that contained
a reference to a psychological process (e.g., operant condi-
tioning); (c) a reference to a treatment manual that was
used to guide the delivery of the treatment; (d) the identi-
fication of active ingredients of the treatment and citations
for these ingredients.
Information sources and search
Primary studies were identified in two ways. We obtained
the 15 studies investigated by Benish et al. [23] and per-
formed a literature search in the databases MEDLINE,
Cinahl Health, Psychology and Behavioral Sciences Collec-
tion, PsycINFO, PsycArticles, PubMed, Social Sciences
Fulltext, and Web of Knowledge, using the keywords
PTSD, posttraumatic, post-traumatic, post traumatic in
combination with psychotherapy and treatment, and
also in combination with relative efficacy, outcome study
and comparative efficacy. We refined the search results by
restricting it to ‘adults’, ‘humans’ and ‘randomized con-
trolled trials’ in some databases (see Fig. 1). In addition,
we searched reference sections of previous meta-analyses
of PTSD treatment, controlled studies of psychotherapy
outcomes for PTSD, and literature reviews of PTSD treat-
ment [31, 35, 36].
Moreover, we meticulously re-assessed the bona fide
status of all treatments included in previous meta-analyses
and of the treatments of the 27 studies included in the
review of Cloitre [31]. This review was specifically men-
tioned by Ehlers et al. [30] in their criticism with regards
to a biased study sample of Benish et al. [23].
Study selection and data collection
Prior to study selection, descriptions of 112 treatments
classified as bona fide in previous meta-analyses on PTSD
[23], alcohol abuse [24], and depression [26] as well as
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descriptions of treatments not classified as bona fide in
these study samples were screened to ensure that we
applied the bona fide criteria correctly. Moreover, we
closely adhered to the descriptions and examples pro-
vided by [29].
The second author extracted the data and coded the
studies. Cases where coding appeared unclear were
resolved by discussion and consensus between both au-
thors. Moreover, coding of included studies was compared
afterwards with coding provided in other meta-analyses
for the same studies, where available [13, 16, 17, 32, 35];
in these cases, no differences in coding were observed.
Wherever possible, intention-to-treat (ITT) analyses were
used in meta-analytical computations.
Data items
Coded and extracted data items pertained to (a) study
characteristics: publication year, type of publication, coun-
try, type of analysis (ITT or completer only); (b) patient
characteristics: total number, number per treatment arm,
percentage of women, mean age, type of trauma, mean time
since trauma, PTSD symptom severity prior to treatment,
percentage of comorbid disorders (depression, anxiety,
substance use disorder), site of patient recruitment (com-
munity, clinical, community and clinical mixed, other), use
of psychotropic drugs; (c) treatment characteristics: type of
treatment, treatment format (individual vs. group), treat-
ment length, total number of sessions, session length; and
(d) all relevant data with regards to the primary and
secondary outcomes, clinically significant change, and
dropout (see the section on Summary Measures, below).
Study quality
Risk of bias was evaluated on the basis of the seven cri-
teria of the Practice Guidelines from the International
Society for Traumatic Stress Studies [37], complemented
by standards of high-quality studies proposed by Cuijpers
et al. [38]. Study quality was evaluated with respect to
whether (1) randomization was conducted adequately and
independently from researchers and therapists (by using,
e.g., computer software); (2) assessment was blinded; (3)
studies reported reasons for dropout or analyses on differ-
ences between dropouts and completers; (4) therapists
were specifically trained in the provided treatment; (5)
adherence to treatment manuals or protocols was
ensured with adequate measures or checked empirically;
Fig. 1 Flow of studies through the selection process
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(6) ITT-analyses were conducted and adequately reported;
(7) a treatment manual or protocol existed. Items were
coded 0 = no, 1 = yes, and summed, resulting in an omni-
bus measure of study quality that ranged from 0 to 7. Add-
itionally, we also investigated criteria (1), (2), and (3)
separately. These criteria agree closely with the Jadad et al.
[39] criteria1 that are widely-used in medical research and
that were already also used in psychotherapy research [16,
22]; with regards to blinding, we considered only blinded
assessment; double-blind trials, as proposed by Jadad et al.
[39] are adequate in medical research, but are generally not
feasible in psychotherapy research.
Summary measures
First, between-group differences in primary and secondary
outcomes (see below) were meta-analysed at post-
treatment and, where available, at follow-up. Benish et
al. [23] restricted their analyses to post-treatment dif-
ferences. All direct measures of PTSD symptom severity
(e.g., Clinician Administered PTSD Scale [CAPS], Impact
of Events Scale [IES], PTSD Symptom Scale Self-Report
[PSS-SR]) were considered primary outcomes. This was in
contrast to Benish et al. [23] who considered measures of
anxiety (e.g., State-Trait Anxiety Inventory [STAI]) primary
outcomes as well. Anxiety is one of the key symptoms of
PTSD and anxiety disorders are among the most frequent
comorbid disorders of PTSD [37]. However, measures of
anxiety do not address the full range of PTSD symptoms.
Hence, they were not considered primary outcomes in the
present study. On the other hand, Benish et al. [23] com-
puted a second effect size, aggregating all post-treatment
outcome measures that were reported in individual studies.
As these included primary outcomes as well, there was a
substantial overlap of this second effect measure with the
primary outcome measure. Instead of following such an
approach, we considered all measures of symptom severity
of comorbid disorders (i.e., anxiety, depression, substance
use disorder), trauma-related symptoms (e.g., trauma-
related guilt), general symptom distress, social functioning,
and quality of life as secondary outcomes, thus having a
true second measure for a more differentiated analysis, see
[6, 9, 10]. Following [12], we also distinguished primary
outcomes with regards to self-reports and clinician ratings.
While the meta-analysis of Van Etten and Taylor [20] did
not find any differences in efficacy with regards to assess-
ment, others did [32, 40]. A complete list of primary and
secondary outcome measures is displayed in Appendix (Ta-
bles 5 and 6).
Second, additional outcomes pertained to treatment
differences in percentages of clinically significant changes
and dropouts at post-treatment and, where available, at
follow-up. Where available, recovery rates were used to
assess clinically significant change. Otherwise, rates of
participants improved were utilized. As in the analysis of
primary and secondary outcomes, data of ITT analyses
were used, where available. Dropout rates were calcu-
lated either on patients dropping out of treatment or
on the basis of ITT participant numbers (i.e., after
randomization).
Categorization of treatments
Based on descriptions and references given in the re-
spective studies, treatments were categorized into spe-
cific types that were in line with previous meta-analyses
[13, 16, 17] and a review [31]. Treatment categorization
in these studies followed a bottom-up strategy, sorting
and clustering treatments according to their provided
descriptions consistently into groups. The present meta-
analysis also adhered to this bottom-up treatment cate-
gorization scheme, adhering as closely as possible to
treatment descriptions in studies for the categorization of
treatments. Similar to previous meta-analyses of PTSD
comparing several treatment categories, categories resulting
from this process were sometimes narrower and sometimes
broader, depending on whether therapies followed a speci-
fied treatment manual (e.g., eye movement desensitization
and reprocessing [EMDR] [41]), or were combined because
of a similar theoretical approach (e.g., exposure therapies).
In order to maximize statistical power, we were careful not
to narrow categories down too much, as this would have
yielded a large number of categories and only few studies
per category. To compensate for this broadening of
categories, we conducted also meta-analyses for distinct
subgroups (see below) and controlled for outliers.
Types of treatment included in the analyses were:
Exposure therapies (EX), prolonged exposure (PE [42]),
and both combined (EXPE), EMDR [41], cognitive
behavioural therapies (CBT), and present-centered
therapies (PCT). PCT included bona fide psychotherapies
that were mostly linked to elements of Roger’s client-
centered psychotherapy [43] and encompassed supportive,
present-centered, problemsolving, and psychoeducative
elements. Treatments coded as CBT included some ther-
apies that utilized, but did not primarily rely on, elements
of other therapies (e.g., exposure [44, 45]), and treatments
such as Seeking Safety [46] or Image Rehearsal [47].
All treatments were coded whether they were trauma
focused (TF) or not (NTF). TF treatments were defined
as focusing on the memory for the traumatic event and/
or on trauma-related appraisals [12]. Najavits and Hien
[48] recommended to name non-trauma focused therapies
for what they are providing and not just to qualify them
for what they are not providing. Nevertheless, we adhered
to TF/NTF distinction as it is frequently used in this field
of research. The TF/NTF distinction served to strictly
compare two categories on the same level of abstraction
and to address the question of whether trauma focused
treatments were more efficacious than non-trauma
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focused ones. Again, treatment descriptions in studies
were utilized as closely as possible to code whether treat-
ments were trauma focused or not. Within the CBT cate-
gory we also examined the efficacy specifically of trauma
focused treatments that included elements of exposure
(TFCBT+ EX).
Synthesis of results
For primary and secondary outcomes, Hedges’ g was used
as effect size measure, similar to previous meta-analyses
[16–18, 32], but in contrast to Benish et al. [23] who used
Cohen’s d. Hedges’ g is widely recommended in the meta-
analytical literature to control for the overestimation of
effects with Cohen’s d in small samples and its use is also
recommended in the Practice Guidelines from the Inter-
national Society for Traumatic Stress Studies [37]. In cases
where studies reported more than one outcome (primary
or secondary), effect sizes were obtained for each outcome
and then averaged within outcomes; dependency between
outcomes was accounted for by assuming a correlation
of .50 in the computation of the variance of the aver-
aged effect size as in Benish et al. [23]. In cases where
both full-scale and subscale scores of a measure were
reported, full-scale scores were used. In cases where
only subscale, but not full-scale, scores were reported,
published coefficients on the intercorrelation of subscales
was used instead of assuming a uniform correlation of .50
in computing the averaged effect size variance (e.g., for
the IES–revised form, coefficients were taken from
[49], p. 1491). For additional outcomes, percentages of
clinically significant changes and dropouts, risk ratios
(RR) were computed and used in analysis.
For all analyses, random-effects models were utilized,
assuming that treatment differences were not repre-
sented by a single population effect. With regards to
analyses themselves, two independent approaches were
utilized: (1) conventional meta-analysis of direct compar-
isons, contrasting specified types of treatment against all
other available treatments, restricted to types with five
or more comparisons, see [38], contrasting also trauma
focused versus non-trauma focused treatments, and con-
trasting further all exposure-based treatments (EXPE)
against all other treatments. The conventional analyses
comprised comparisons regarding primary and second-
ary outcomes, clinical significance, and dropout as well
as analyses of publication bias, sensitivity analyses, and
moderator analyses; (2) the Wampold homogeneity test
(WHT) with regards to primary and secondary outcomes
at post-treatment [4, 50].
For conventional meta-analyses, the software metafor
[51] in R was used. Heterogeneity was tested with the Q
test and assessed with the I2 statistic that describes the
ratio of true heterogeneity to the total observed disper-
sion with a range of 0 % to 100 %, reporting also 95 %
confidence intervals. Heterogeneity was assumed small
for I2 = 25 %, moderate for I2 = 50 %, and high for I2 =
75 % [52].
With regards to the interpretation of standardized
mean differences, i.e., Hedge’s g, we adhered to bench-
marks of Cohen [53] interpreting g = 0.20 as small, .50 as
medium, and 0.80 as large effects. For the interpretation
of whether effects are likely clinically meaningful, we
adhered to Ferguson [54] and the NICE Guideline
Development Group [12] who proposed thresholds of
g = .41 and g = .50, respectively. With regards to the
interpretation of risk ratios pertaining to recovery/im-
provement rates and dropout, we adhered to thresholds
devised by the NICE Guideline Development Group [12],
regarding risk ratios ≤ 0.80 or ≥ 1.25 as clinically mean-
ingful. Where 95 % confidence intervals of risk ratios
included these thresholds, results were interpreted as
‘limited evidence’ of differential efficacy. Significance
was set to p < .05.
The omnibus hypothesis, whether there were any dif-
ferences in treatment efficacy overall, regardless of treat-
ment categorization, was investigated with the WHT.
The WHT requires in a first step the random assignment
of a positive (+) or negative sign (−), in equal proportion
[4], to the effect sizes of the head-to-head comparisons.
The aggregated effect of the randomly aligned treatment
differences will approach zero if k, the number of com-
parisons, is large, but this is not of direct interest in the
WHT. In the second, crucial, step, the homogeneity of
the obtained effect size distribution is investigated via
the Q test. If the null hypothesis of no overall treatment
differences is not true, then there should be a dispro-
portionate number of observations in the tails of the
distribution [4]. Therefore, if homogeneity has to be
rejected, the null hypothesis of no overall treatment
differences must also be rejected. This null hypothesis
has been tested with the WHT in a number of previous
analyses [4, 23–25] and has never been rejected.
However, two aspects may compromise the validity of
the WHT: (1) the Q test is known for its low test power
when k is small [52]; in the meta-analysis of Benish et al.
[23] k was 17, heterogeneity may thus have been over-
looked in previous research; (2) the WHT relies on only
one run of random sign assignment. As stated above,
random assignment need not result in an aggregated ef-
fect size of null; the probability of this event approaches
unity only for k→∞. Calculation of the Q statistic de-
pends on the aggregated effect size. Random fluctuations
of the aggregated effect size thus affect also the Q test of
the WHT. Performing the WHT only once for a given
dataset may therefore capitalize on random fluctuations
whose possible effect is greater for small k. In conclu-
sion, the Q test of the WHT cannot be considered an
exact test, and Q values, as well as I2 values derived from
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this Q statistic, cannot be considered exact statistics of
effect size heterogeneity.
In the present study, we sought to overcome this prob-
lem by applying the WHT repeatedly on 30 independent
runs of random sign assignments, which can be thought
of as a Monte Carlo permutation test. Monte Carlo per-
mutation tests are akin and asymptotically equivalent to
(exact) permutation tests (i.e., Fisher’s exact test) which
obtain the distribution of a test statistic under the null
hypothesis by calculating all possible values of this statis-
tic by rearranging (i.e., permuting) the observed data in
all possible ways. P values are obtained by computing
the proportion of test statistic values that are greater
than the test statistic of the observed data. Monte Carlo
permutation tests sample only a number of permutations
and do not perform all possible permutations. In the
present case and with regards to the WHT, no clearly
defined test statistic could be computed for the observed
data: as explained above, the Q statistic of the WHT is
itself not exact, but intrinsically fuzzy and subject to ran-
dom fluctuations. However, the principles of Monte
Carlo permutation tests could be applied to sample the
distribution of Q values of the WHT and to obtain the
number of significant Q tests for a given data set. In-
stead of relying on the p value of a single WHT, we
counted the number of p values that were less than .05
among 30 replications of the WHT. Assuming the null
hypothesis of no overall treatment differences is true, we
expected 1.5 significant results (5 % of 30) with a nom-
inal α of .05. To determine whether the null hypothesis
of the WHT had to be rejected, the obtained number of
significant results among the 30 replications was com-
pared to this expected value, using a binomial test. This
test had a power of more than 95 % to reject the null hy-
pothesis of the WHT of no overall treatment differences,
if the true number of significant Q values was at least
7.5 (i.e., 25 % of Q tests were significant).
Publication bias
Publication bias in meta-analysis has to be investigated
in order to check whether studies in the analysis are rep-
resentative of the overall population of completed studies.
A systematic bias could occur either because of one-sided
search-strategies or because small studies or studies with-
out significant results were not published on a regular
basis. Publication bias was investigated with the trim-and-
fill procedure [55] with regards to all meta-analyses of
direct comparisons, using metafor in R.
Additional analyses
Dependencies in the data
One of the studies (see Results) contained three com-
parisons. In order to test and correct for this dependence,
all meta-analyses of direct comparisons involving these
three comparisons were repeated, keeping only the head-
to-head comparison with the largest effect. Three other
studies (see Results) compared treatments of the same
type. Meta-analyses of direct comparisons involving these
studies were repeated as well, excluding these studies.
Sensitivity analyses
Furthermore, overall stability of meta-analyses of direct
comparisons was examined with sensitivity analysis using
the leave-one-out method, investigating whether there
were influential outliers in the data. All of these analyses
were used to investigate the robustness of obtained results
and to adjust for possible outliers that may otherwise bias
and distort results.
Moderator analyses
Moderator analyses were carried out for meta-analyses
of direct comparisons to explain unobserved heterogeneity,
using mixed-effects models in cases where more than ten
comparisons were available [38], testing for effects of study
quality [12, 16], type of analysis (ITT vs. completer only)
[12], participant sex (male vs. female vs. mixed) and pro-
portion of women [12, 19, 21], type of trauma [19, 21],
time since trauma [16], PTSD symptom severity prior to
treatment [56] (severe vs. extreme), and treatment length
and total number of sessions [16, 32].
Results
Study selection and study characteristics
In addition to the 15 studies included in Benish et al.
[23], we retrieved seven further studies that fulfilled the
inclusion criteria, resulting in a total sample of 22 studies
[42, 44–47, 57–73] (as the re-assessment of the study selec-
tion is an important topic of interest, see Additional file 1
for full references of the excluded studies). In sum, 161
abstracts were thoroughly screened and 46 studies
assessed in full-text for eligibility, see Fig. 1.
Studies were excluded because they (reference num-
bers pertain to the reference list in Additional file 1: (a)
compared treatments that were not bona fide [1–5]2; (b)
were component or dismantling studies [6–12]3; (c)
reported preliminary analyses of studies that were not
included in the present meta-analysis themselves [13]; (d)
reported additional analyses on data of studies already
included in the present meta-analysis [14–17]; (e) did not
examine adults and/or did not ascertain a PTSD diagnosis
according to DSM-III or DSM-IV [18–20]; (f) included
treatments that were delivered in a standard protocol that
could not be adapted to individual patients [21–23]; (g)
examined only two participants in one treatment arm
[24]. This study [24] was excluded on statistical grounds
as estimates of population variance, on which Hedges’
g depend, are undefined when n < 3.
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From the studies included in the review of Cloitre
[31], only 3 studies remained which fully met the inclu-
sion criteria and therefore were also included in the
present meta-analysis [46, 65, 71]. Deviating from Benish
et al. [23], the Schnurr et al. [71] study was included.
This study investigated a PCT about which Wampold et
al. [29] argued it was not bona fide because it bore little
resemblance to PCT commonly applied in practice.
However, according to the information provided in the
study itself, the treatment fulfilled enough criteria (b, c,
and d; see the section on Eligibility, above) to be consid-
ered bona fide. Moreover, Benish et al. [23] included an-
other study of the same authors [70] that contained
basically the same treatment, only delivered in a group
format. On these premises, the Schnurr et al. [71] study
was therefore included.
Basic characteristics of the 22 included studies, quality
ratings, and individual effect sizes of primary and sec-
ondary outcomes are displayed in Table 1. Overall, 1694
patients participated in the studies. Studies were pub-
lished between 1989 and 2010 and 18 (82 %) were con-
ducted in English-speaking countries, 11 of which in the
United States. Patients’ mean age ranged from 21.5 to
59.4 years, seven studies contained only women (total
n = 664), three studies only men (total n = 460), in the
remaining 12 studies (total n = 570) on average 56.0 %
of patients were female. Twelve studies included pa-
tients with a specific trauma history or otherwise spe-
cific patient characteristics (total n = 1175): Childhood
sexual abuse and adult rape victims (five studies, total
n = 305), war veterans (four studies, total n = 744), fugi-
tives (two studies, n = 51), comorbid substance use disorder
(one study, n = 75). Fourteen studies provided information
on time since trauma, which ranged from 1.2 to 22.9 years,
with a mean of 7.1 years. With regards to PTSD symptom
severity prior to treatment, eleven studies included severely
traumatized patients (total n = 902; CAPS: 60–79,
IES > 43), five studies included extremely traumatized
patients (total n = 556; CAPS > 79). The remaining six
studies did not report on severity or used instruments
that provide no cut-offs with regards to severity (i.e., PDS,
PSS-I, PSS-SR, PCL).
Details regarding the categorization of treatments in
the present meta-analysis and in previous meta-analyses
are reported in Appendix (Table 7). The psychodynamic
therapy investigated in Brom et al. [57] was neither cate-
gorized with regards to type of treatment, as it did not fit
with any type, nor included in direct head-to-heads com-
parisons of TF and NTF treatments as it remained unclear
whether or not it was trauma focused [29]; it served only
as an available comparator in meta-analyses of direct
comparisons of specific treatment types. The hypno-
therapy investigated in Brom et al. [57] was categorized
as EX, as the description in the study explicitly stated
that “The emphasis of the hypnotherapists in our study
was on behavioral therapy. The goal was to bring the
patient in contact with the reality of the traumatic
event and to bring about a decrease in the conditioned
responses triggered by the event” (p. 607) and that hypno-
sis was used to facilitate this goal (meta-analyses [12, 13]
coded this treatment as ‘other’ treatment). The Hien et al.
[46] study investigated the efficacy of Seeking Safety, a
manualized CBT that addresses both PTSD and substance
use disorder, comparing it with another CBT (relapse pre-
vention) that addresses only substance use disorder. Both
treatments were coded as CBT, but in the CBT related
meta-analyses only Seeking Safety was pooled with the
other CBT treatments for PTSD (and contrasted with re-
lapse prevention), as relapse prevention did not directly
address the PTSD symptomatology.
Twenty-four head-to-head comparisons were reported
in the 22 studies; one study compared three treatments.
There were 15 comparisons involving CBT (of these, 10
were TFCBT + EX), seven involving EX, seven involving
PE, six involving EMDR, and six involving PCT. Therapies
were conducted in 12 sessions that lasted 90 min on aver-
age. Only four (8.9 %) treatments were carried out in a
group format. Follow-up assessments were reported in all
(100 %) studies with regards to at least one of the defined
outcomes; time of follow-up ranged from 1 to 15 months
after end of treatment, 4.7 months on average. Nine
(40.9 %) studies reported a second follow-up, ranging 6
to 24 months after end of treatment, 10.0 months on
average.
Study quality
Ratings of study quality are presented in Table 1. Most
studies reported reasons for dropout or reported analyses
of differences between completers and dropouts, ensured
adherence to treatment manuals or protocols, and pro-
vided a treatment manual or protocol (18 [81.8 %] studies
each). Fifteen (68.2 %) studies each reported blinded as-
sessment and whether therapists were specifically trained
in the provided treatment. Only eight (36.4 %) studies
reported adequate randomization, whereas only seven
(31.8 %) intention-to-treat analyses. Jadad ratings ranged
between 0 and 4 points, with 2.2 points on average.
Synthesis of results
Primary and secondary outcomes: Conventional meta-analysis
of direct comparisons
Table 2 displays meta-analyses with regards to primary
and secondary outcomes at post-treatment. No specific
type of treatment had a higher efficacy than other avail-
able comparison treatments. However, PCTs were less
efficacious with regards to primary, but not secondary,
outcomes than their available comparison treatments.
Trauma focused treatments were in direct head-to-head
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Table 1 Characteristics of included studies
Study n per study arm
(dropout)
Compared treatments (plus categorization) Study quality & Jadad
score
Primary outcome (at post-
treatment)
Secondary outcome (at post-
treatment)
Brom et al. [57] 31(4)/29(4)/29(4) Trauma desensitization (EX; TF) vs. brief
psychodynamic therapya vs. hypnotherapyb (EX; TF)
0/0/+/+/0/0/0: 1 1 vs. 2: −0.26 [−0.80, 0.29] 1 vs. 2: 0.23 [−0.19, 0.65]
1 vs. 3: −0.26 [−0.81, 0.28] 1 vs. 3: 0.02 [−0.40, 0.43]
2 vs. 3: −0.05 [−0.60, 0.51] 2 vs. 3: −0.22 [−0.64, 0.21]
Bryant et al. [58] 31(8)/28(6) Imaginal EX (TF) vs. in vivo EX (TF) +/+/+/+/+/+/+: 4 0.05 [−0.37, 0.47] 0.16 [−0.25, 0.58]
Cook et al. [47]c 61(22)/63(12) Imagery Rehearsal (CBT; TFCBT + EX; TF) vs.
Sleep & Nightmare Management (CBT)
+/+/+/+/+/+/+: 4 −0.10 [−0.41, 0.20] −0.09 [−0.36, 0.18]
Cottraux et al. [59]c 31(4)/29(14) CBT (TFCBT+EX; TF) vs. Rogerian supportive therapy (PCT) +/+/+/+/0/0/+: 4 −0.05 [−0.68, 0.58] −0.16 [−0.63, 0.30]
Devilly & Spence
[60]
15(3)/17(6) Cognitive-behavior trauma treatment protocol
(CBT; TFCBT + EX; TF) vs. EMDR (TF)
0/0/+/+/+/0/0: 1 −0.58 [−1.24, 0.09] −0.29 [−0.96, 0.39]
Foa et al. [42]c 17(3)/14(4) Stress inoculation training (CBT) vs. PE (TF) 0/+/+/+/+/0/+: 2 −0.54 [−1.37, 0.29] −0.22 [−0.89, 0.44]
Foa et al. [61]c 26(7)/25(2) Stress inoculation training (CBT) vs. PE (TF) 0/+/+/+/+/0/+: 2 0.14 [−0.46, 0.75] 0.62 [−0.08, 1.16]
Hien et al. [46]c 41(16)/34(10) Seeking Safety (CBT) vs. relapse prevention (CBT) 0/0/0/+/+/+/+: 0 0.32 [−0.04, 0.69] 0.18 [−0.27, 0.64]
Ironson et al. [62] 10(0)/12(6) EMDR (TF) vs. PE (TF) 0/0/+/0/+/0/+: 1 −0.62 [−1.55, 0.31] −1.29 [−2.30, −0.28]
Lee et al. [63] 13(1)/13(1) Stress inoculation training + PE (CBT; TFCBT + EX; TF)
vs. EMDR (TF)
0/0/0/+/+/0/+: 0 0.53 [−0.14, 1.19] 0.52 [−0.30, 1.33]
Marks et al. [64] 19(1)/23(3) Cognitive restructuring (CBT; TF) vs. PE (TF) 0/+/+/0/+/0/+: 2 0.07 [−0.55, 0.70] 0.19 [−0.34, 0.72]
McDonagh et al.
[44]c
29(12)/22(2) CBT (TFCBT + EX; TF) vs. problem solving therapy (PCT) 0/+/+/+/+/+/+: 2 0.22 [−0.33, 0.78] 0.22 [−0.21, 0.64]
Neuner et al. [65]c 17(2)/14(1) Narrative exposure therapy (CBT; TFCBT + EX; TF)
vs. supportive counselling (PCT)
+/+/+/+/+/0/0: 4 −0.06 [−0.80, 0.68] −0.23 [−0.98, 0.52]
Paunovic & Öst [66] 10(3)/10(1) CBT (TFCBT + EX; TF) vs. EX (TF) 0/0/+/0/0/0/0: 1 −0.20 [−0.94, 0.54] −0.29 [−1.05, 0.47]
Power et al. [45] 37(16)/39(12) Cognitive restructuring + EX (CBT; TFCBT + EX; TF)
vs. EMDR (TF)
+/+/+/+/+/0/+: 4 0.55 [0.07, 1.02] 0.56 [0.10, 1.02]
Ready et al. [67]c 6(1)/5(1) Virtual reality EX (TF) vs. PCT 0/+/+/0/0/0/+: 2 −0.51 [−1.86, 0.84] −1.62 [−3.26, 0.02]
Resick et al. [68] 62(11)/62(12) Cognitive processing (CBT; TFCBT + EX; TF) vs. PE (TF) 0/0/+/+/+/+/+: 1 −0.27 [−0.57, 0.04] −0.46 [−0.74, −0.18]
Rothbaum et al.
[69]
25(5)/23(3) EMDR (TF) vs. PE (TF) 0/+/0/0/+/0/+: 1 0.34 [−0.17, 0.85] 0.50 [0.00, 1.00]
Schnurr et al. [70]c 162(44)/163(28) Trauma-focused group therapy (CBT; TFCBT + EX; TF)
vs. PCT group therapy
+/+/+/0/+/+/+: 4 −0.12 [−0.31, 0.07] 0.00 [−0.17, 0.17]
Schnurr et al. [71]c 143(30)/141(53) PCT vs. PE (TF) +/+/+/+/+/+/+: 4 0.31 [0.11, 0.51] 0.14 [−0.05, 0.33]
Tarrier et al. [72] 37(4)/35(6) Cognitive therapy (CBT; TF) vs. imaginal EX (TF) +/+/0/0/+/0/+: 3 0.17 [−0.22, 0.57] 0.07 [−0.36, 0.50]
Taylor et al. [73] 19(4)/22(7) EMDR (TF) vs. EX (TF) 0/+/+/+/+/0/+: 2 0.32 [−0.30, 0.94] 0.17 [−0.40, 0.74]
Note. aNot categorized with regards to type of treatment; bcategorized according to description given in study; cused for comparison of TF versus NTF therapies. Figures of study quality correspond to ratings (+: present; 0: absent)
whether (1) randomization was adequate, (2) assessment was blinded, (3) reasons for dropout or analyses on differences between dropouts and completers were reported, (4) therapists were trained in the provided treatment, (5)
adherence to treatment manuals or protocols was ensured with adequate measures or checked empirically, (6) ITT-analyses were conducted and adequately reported, (7) a treatment manual or protocol existed (in this order); Jadad
scores (min = 0, max = 4), based on these ratings, are reported after the colon. Outcomes correspond to estimates of Hedges’ g along with 95 % confidence intervals; g> 0 signifies that effects at post-treatment were larger for the













comparisons to non-trauma focused treatments (TF vs.
NTF) significantly more efficacious in primary outcomes.
Heterogeneity appeared low for exposure therapies, for
the head-to-head comparisons of TF vs. NTF and PCTs,
but medium-to-high in both outcomes, and mostly signifi-
cant according to the Q test, for CBT, prolonged exposure,
and EMDR. Distinguishing between self-reports and
clinician ratings did not reveal deviating results for any
specific type of treatment (details omitted for brevity),
but for the head-to-head comparisons of TF vs. NTF
treatments: At post-treatment, TF treatments were
more efficacious than NTF treatments in self-reports,
k = 5, g = 0.21 [0.05, 0.37], p = .008, Q = 3.00, p = .557,
I2 = 13 %.
Meta-analyses with regards to primary and secondary
outcomes at follow-up (first and second follow-ups) are
presented in Appendix (Table 8). TF treatments were
again more efficacious than NTF treatments at both
follow-ups. Pointing into the same direction, TFCBT + EX
treatments appeared to be more efficacious with regards
to primary outcomes at both follow-ups, but these results
closely missed significance (ps = .053 and .076). PCTs were
again less efficacious with regards to primary outcomes at
first follow-up. Heterogeneity was again low for exposure
therapies, TF vs. NTF, and PCTs, but medium-to-high
for CBT, TFCBT + EX, prolonged exposure, and EMDR.
Heterogeneity was also high for CBT at second follow-up.
TF treatments were more efficacious than NTF treat-
ments at first follow-up both in self-reports (k = 5, g = 0.15
[0.01, 0.29], p = .037, Q = 1.84, p = .766, I2 = 0 %) and in
clinician ratings (k = 6, g = 0.18 [0.03, 0.33], p = .016, Q =
2.58, p = .765, I2 = 0 %).
Primary and secondary outcomes: the Wampold
homogeneity test (WHT)
Primary and secondary outcomes at post-treatment were
also investigated with the WHT. In 30 independent runs
of random sign assignment with regards to primary
outcomes, the Q test was only twice not significant
(p > .05) and yielded in 28 replications a significant value
(p < .05); the null hypothesis of no differences in treatment
efficacy had to be rejected with p < .001 (binomial test).
On average, I2 was 40 % across all replications, with a
range of 28 % to 43 %. With regards to secondary out-
comes, Q tests were significant in all of another 30 inde-
pendent runs (p < .001); on average, I2 was 43 %, ranging
from 35 % to 46 %. Restricting the study sample to studies
that were also included by Benish et al. [23], we obtained
20 significant Q tests out of another 30 independent runs
for primary outcomes (p < .001); on average, I2 was
38 %, ranging from 27 % to 43 %. In contrast, Benish et
Table 2 Meta-analyses of the efficacy of different types of treatment at post-treatment regarding primary and secondary outcomes
Treatments k Hedges’ g p Q p I2
Cognitive behavior therapy (all) 15 −0.02 [−0.17, 0.14] .843 21.89 .081 38 % (0–64 %)
−0.03 [−0.18, 0.13] .735 26.25 .024 50 % (5–70 %)
Trauma focused cognitive behavior therapy
with exposure (subgroup)
10 0.03 [−0.15, 0.22] .724 14.86 .095 42 % (42–88 %)
Exposure 10 0.03 [−0.17, 0.23] .802 20.05 .018 59 % (59–90 %)
7 0.17 [−0.04, 0.37] .112 4.14 .658 0 % (0–58 %)
−0.06 [−0.24, 0.13] .556 6.22 .399 0 % (0–72 %)
Prolonged exposure 7 0.01 [−0.26, 0.28] .927 14.98 .020 55 % (13–82 %)
−0.02 [−0.39, 0.35] .914 26.70 .0002 82 % (54–89 %)
Exposure + prolonged exposure 14 0.10 [−0.07, 0.26] .240 19.33 .113 33 % (0–63 %)
−0.02 [−0.20, 0.17] .853 33.18 .002 57 % (31–78 %)
EMDR 6 0.01 [−0.45, 0.48] .959 17.02 .005 70 % (35–87 %)
0.17 [−0.32, 0.66] .505 17.97 .003 73 % (39–87 %)
Present-centered therapies 6 −0.17 [−0.32, 0.00] .038 4.38 .496 15 % (0–72 %)
−0.04 [−0.15, 0.07] .468 5.39 .370 0 % (0–77 %)
TF vs. NTF 9 0.14 [0.01, 0.27] .030 7.31 .504 8 % (8–80 %)
0.06 [−0.04, 0.15] .269 9.16 .329 0 % (0–96 %)
Note. k = number of comparisons; Q = statistic of effect size heterogeneity. Values of Hedges’ g and I2 are presented alongside their 95 % confidence intervals.
Hedges’ g > 0 signifies a higher efficacy for the type of treatment of interest compared to all other available treatments, Hedges’ g < 0 signifies a lower efficacy.
Per type of treatment, values in the first line pertain to primary outcomes (i.e., PTSD symptom severity), values in the second line to secondary outcomes
(i.e., symptom severity of comorbid disorders, trauma-related symptoms, general symptom distress, social functioning, and quality of life)
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al. [23] reported a not significant I2 of 9.39 % for this
sample of studies.
Clinical significance and dropout
Table 3 displays meta-analyses with regards to clinical
significance and dropout at post-treatment. Additionally,
the thresholds for clinically meaningful results [12] of
RR ≤ 0.80 or RR ≥ 1.25 were considered for interpretation
(see the Synthesis of results subsection in the Methods
section): Where 95 % confidence intervals of risk ratios
included these thresholds, results were interpreted as
limited evidence of differential efficacy. Clinical signifi-
cance could not be examined for exposure therapies and
PCTs because of less than five comparisons available each.
Treatments did not differ with regards to clinical signifi-
cance or dropout. Trauma focused treatments appeared to
have a higher efficacy than non-trauma focused treatments,
but this result closely missed significance (p = .095). Hetero-
geneity was low for most treatments in clinical significance,
but medium-to-high for prolonged exposure and EMDR.
In contrast, heterogeneity was medium-to-high in dropout
for most treatments, with the exception of EMDR, where
heterogeneity was low.
With regards to the required five or more available
comparisons, 13 studies reported rates of recovery or
improvement at a first follow-up, while only four reported
respective rates for two follow-ups [44, 59, 68, 71]. One
overall follow-up was defined and investigated, using data
from the second follow-up in studies that reported two
follow-ups. PCTs could not be investigated at post-
treatment; at follow-up PCTs appeared to be less effi-
cacious, k = 5, RR = 0.79 [0.61, 1.02], p = .076, Q = 6.84,
p = .144, I2 = 35 %, but this result closely missed signifi-
cance. Trauma focused therapies appeared to be more
efficacious at follow-up than non-trauma focued treat-
ments, k = 6, RR = 1.21 [0.98, 1.49], p = .076, Q = 7.00,
p = .221, I2 = 15 %, but this result also closely missed
significance. The only other treatment type, for which
five or more comparisons were available, was CBT. CBT
did neither differ from other treatments concerning rates
of recovery or improvement at follow-up, k = 9, RR =
1.12 [0.96, 1.30], p = .153, Q = 10.03, p = .263, I2 = 0 %;
nor was the subgroup TFCBT+ EX significantly more effi-
cacious than comparison treatments, k = 7, RR = 1.14
[0.96, 1.34], p = .126, Q = 9.73, p = .136, I2 = 0 %.
Publication bias
Mostly, there was no indication that publication bias influ-
enced results substantially (details omitted for brevity).
However, with regards to primary outcomes, trim-and-fill
added one missing study in comparisons of PCTs. This
resulted in an overall treatment effect of g = −0.20
Table 3 Meta-analyses of the efficacy of different types of treatment at post-treatment regarding clinical significance and dropout
Treatments k RR p Q p I2
Cognitive behavior therapy (all) 11(7) 0.95 [0.83, 1.08] .453 11.47 .322 0 % (0–47 %)
15 1.20 [0.86, 1.68] .281 24.17 .044 43 % (0–67 %)
Trauma focused cognitive behavior therapy
with exposure (subgroup)
7 1.00 [0.85, 1.17] .994 8.22 .223 0 % (0-94 %)
10 1.26 [0.79, 2.01] .341 18.73 .028 61 % (0-92 %)
Exposure – – – – – –
7 1.12 [0.69, 1.79] .666 3.01 .808 0 % (0–43 %)
Prolonged exposure 7(5) 1.13 [0.84, 1.52] .415 16.05 .014 67 % (19–83 %)
7 1.25 [0.76, 2.03] .380 11.19 .083 39 % (0–75 %)
Exposure + prolonged exposure 9(6) 1.13 [0.89, 1.43] .312 18.58 .017 58 % (13–79 %)
14 1.22 [0.90, 1.67] .201 14.91 .313 16 % (0–46 %)
EMDR 6(3) 1.06 [0.76, 1.48] .733 14.51 .013 67 % (22–85 %)
6 0.83 [0.53, 1.28] .397 5.27 .384 0 % (0–77 %)
Present-centered therapies – – – – – –
6 0.77 [0.33, 1.80] .554 14.56 .012 82 % (22–85 %)
TF vs. non-TF 6(4) 1.31 [0.95, 1.79] .095 9.69 .084 46 % (0–77 %)
9 1.01 [0.53, 1.92] .981 28.90 .0003 79 % (40–95 %)
Note. k = number of comparisons, with regards to clinical significance (first line), the number in parentheses refers to the number of comparisons that were based
on recovery rates; RR = risk ratio; Q = statistic of effect size heterogeneity. RRs and I2 are presented alongside their 95 % confidence intervals. RR > 1 signifies a
higher rate of clinical significant change/dropout for the type of treatment of interest compared to all other available treatments, RR < 1 signifies a lower rate.
Per type of treatment, values in the first line pertain to clinical significance (i.e., recovery rates or rates of patients improved), values in the second line to dropout
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[−0.05, −0.35], p = .011, for PCTs which suggests that
they were robustly less efficacious than other available
comparison treatments. Trim-and-fill added two missing
studies in comparisons of prolonged exposure with regards
to clinical significance, three missing studies in compari-
sons of exposure therapies with regards to dropout, and
one missing study in comparisons of prolonged exposure
with regards to dropout. None of these corrections altered
previous results substantially (details omitted for brevity).
Dependencies in the data
Excluding studies in cases where more than one com-
parison was reported [57] or where treatments of the
same type were compared [46, 47, 58] did not change re-
sults substantially for any of the above reported analyses
(details omitted for brevity). Thus, categorizing the hypno-
therapy investigated in Brom et al. [57] as EX, which may
appear debatable, did not influence overall results.
Sensitivity analyses
A number of studies were identified as influential cases
in sensitivity analyses. Some influential studies were of
higher quality and examined larger samples than the
remaining studies [45, 59, 71], see Table 1. Hence, their
exclusion may not be considered warranted in every
comparison where they appeared to be influential. Others
were of a comparably lower quality [62, 68], indicating
that exclusion of these studies might be considered war-
ranted in comparisons where they appeared influential.
With regards to primary outcomes at post-treatment,
studies of Resick et al. [68] and Schnurr et al. [70, 71]
appeared influential in the PE, EXPE and PCT categories.
Excluding either the Resick et al. [68] or the Schnurr et al.
[71] study rendered heterogeneity in comparisons of
prolonged exposure not significant, I2 = 27 % and 29 %,
respectively. Moreover, excluding the Resick et al. [68] study
from comparisons of the combined EXPE category indi-
cated a higher efficacy of treatments of this type, g = 0.19
[0.06, 0.33], p = .005, and diminished also heterogeneity to
I2 = 2 %. Notably, the Resick et al. [68] study was of com-
parably low quality; hence, exclusion may be considered
warranted, suggesting thus a true advantage of EXPE treat-
ments over other treatments. Excluding either the Schnurr
et al. [70] or the Schnurr et al. [71] study from comparisons
of PCT rendered the overall treatment effect not significant,
g = 0.16 [−0.10, 0.42], p = .220, and g = 0.09 [−0.08, 0.26], p
= .290, respectively.
With regards to secondary outcomes at post-treatment,
studies of Foa et al. [61], Power et al. [45], and, again,
Resick et al. [68] were influential. Excluding either of these
studies rendered heterogeneity in comparisons of CBT
not significant, I2 = 46 %, 39 %, and 0 %, respectively.
With regards to clinical significance at post-treatment,
studies of Ironson et al. [62], and, again, Schnurr et al.
[70] and Schnurr et al. [71] were influential. Excluding
the Schnurr et al. [71] study rendered heterogeneity in
prolonged exposure and in the combined EXPE category
not significant, I2 = 19 % and 14 %, respectively. Excluding
the Ironson et al. [62] study rendered heterogeneity there
also not significant, I2 = 39 % and 37 %, respectively, and
resulted in limited evidence for a higher efficacy of these
treatments, RR = 1.26 [1.02, 1.57], p = .035 (PE), and RR =
1.22 [1.01, 1.48], p = .043 (EXPE), respectively. As the
Ironson et al. [62] study was of low quality, exclusion may
be considered warranted, suggesting thus a true advantage
of prolonged exposure over other treatments (the
advantage of EXPE appeared to be driven by prolonged
exposure). Furthermore, exclusion of the Schnurr et al.
[70] study resulted in limited evidence for a higher effi-
cacy of trauma focused treatments as well, RR = 1.46
[1.03, 2.08], p = .034. Finally, exclusion of the Cottraux et al.
[59] study resulted in limited evidence for a higher risk of
dropout for CBT, RR = 1.38 [1.11, 1.72], p = .005, and for
TFCBT+ EX, RR = 1.46 [1.14, 1.88], p = .003 and a lower
risk of dropout for PCT, RR = 0.57 [0.43, 0.75], p < .001.
Moderator analyses
Moderator analyses revealed effects of study quality
(Jadad rating) on primary outcomes at follow-up and of
secondary outcomes at post-treatment in comparisons of
CBT with other treatments. Studies with lower quality
reported larger treatment differences, see Table 4. This
Table 4 Moderator analyses: efficacy of CBT according to study quality
Primary outcomes at follow-up Secondary outcomes at post-treatment
Quality ratinga k Hedges’ g p k Hedges’ g p
0 2 0.44 [0.77, 0.13] .006 2 0.26 [−0.14, 0.66] .196
1 3 −0.31 [−0.57, −0.04] .023 3 −0.43 [−0.66, −0.18] < .001
2 4 0.09 [−0.28,0,46] .630 4 0.21 [−0.05, 0.46] .108
3 1 −0.09 [−0.50, 0.33] .672 1 0.03 [−0.38, 0.44] .882
4 4 −0.09 [−0.25, 0.07] .252 5 0.02 [−0.11, 0.15] .744
Note. k = number of included studies. Values of Hedges’ g are presented alongside their 95 % confidence intervals. Hedges’ g > 0 signifies a higher efficacy for CBT
compared to all other available treatments, Hedges’ g < 0 signifies a lower efficacy. Heterogeneity explained by quality rating in primary outcomes: QM (5) = 14.42,
p = .013; residual heterogeneity: QE(9) = 10.88, p= .284; in secondary outcomes: QM(5) = 16.14, p< .001; QE(10) = 10.13, p= .429. a Quality rating according to Jadad et al. [39]
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pattern was also similar for secondary outcomes at
post-treatment in comparisons of TFCBT + EX with
other treatments (QM (3) = 13.59, p = .004; QE(7) = 7.20,
p = .408; details omitted for brevity). Moreover, time since
trauma was another moderator of secondary outcomes at
post-treatment in comparisons of CBT with other treat-
ments (slope = −0.09 [−0.16, −0.03], p = .003; QM (1) =
9.09, p = .003; QE(8) = 7.24, p = .512; similar for compari-
sons of TFCBT + EX with other treatments: slope = −0.15
[−0.23, −0.08], p < .001; QM (1) = 15.31, p < .001; QE(5) =
2.21, p = .820): Treatment differences were in favour of
CBT (g > 0) in studies where time since trauma was less
than four years, and in favour of comparative treatments




In head-to-head comparisons between trauma focused
treatments and non-trauma focused treatments, this
meta-analysis revealed a significant difference in effi-
cacy. Trauma focused treatments were slightly more
efficacious with regards to PTSD symptom severity at
post-treatment (g = 0.14), at the first (g = 0.17) and the
second follow-up (g = 0.23). This result corresponds with
results of other meta-analyses [12, 14], but this time
based strictly on head-to-head comparisons of bona
fide therapies only.
The results of this meta-analysis with regards to the
specific types of therapy corroborate at a first glance
that bona fide psychotherapies of PTSD appear mostly
similar with regards to their efficacy [23]. There was no
strong indication of cognitive behavioural therapy,
exposure therapies, prolonged exposure, EMDR, or of
trauma focused cognitive behavioural therapy to be
more efficacious than any of the other available ther-
apies. However, sensitivity analyses revealed that some
of these null findings could be traced to low quality
studies. Excluding these studies, we obtained evidence
of an advantage of prolonged exposure and exposure
therapies (g = 0.19) over other treatments considering
PTSD symptom severity at post-treatment, and limi-
ted evidence of a higher efficacy of prolonged exposure
(RR = 1.26) regarding recovery rates at post-treatment,
cf. [16]. PCTs appeared somewhat less efficacious than
other treatments with regards to PTSD symptom se-
verity at post-treatment (g = −0.20; adjusting for publi-
cation bias) and at follow-up (g = −0.17), mirroring
recent findings with regards to a somewhat diminished
efficacy of bona fide supportive therapies also in the
treatment of depression [27]. However, PCTs were
equally effective with regards to secondary outcomes
as their available comparison treatments. No signifi-
cant and clinically meaningful differences with regards
to dropout were observed. All differential treatment ef-
fects were at most only small in size [53] and far below
proposed thresholds for clinically meaningful differ-
ences [12, 54].
Application of the omnibus test of overall effect size
heterogeneity (see Benish et al. [23]) indicated that the
null hypothesis of no treatment differences had to be
rejected in the full study sample; effect size heterogen-
eity was larger than expected by chance. Similarly, this
null hypothesis had to be rejected in the study sample
of Benish et al. [23]. Our analysis was based on an
improved application of this analytic method, using a
Monte Carlo permutation approach and basing our
conclusions on 30 independent runs of the Wampold
homogeneity test, and differed also by utilizing a stric-
ter definition regarding primary outcomes. Despite
these differences, the obtained results cast doubt on the
results of the Benish et al. [23] meta-analysis, but also
on other meta-analyses that used this method [4, 24,
25, 33]. We thus caution on the inconsiderate applica-
tion of the omnibus test of overall effect size hetero-
geneity and recommend a Monte Carlo permutation
approach, as used in the present study, also in future
applications.
Substantial effect size heterogeneity was also ap-
parent in conventional meta-analyses of specific
treatment types and sensitivity analyses revealed that
it could be traced to a number of influential studies.
The Schnurr et al. [71] study was identified as influ-
ential, being subject to controversy before [29, 30],
regarding the bona fide status of the PCT investi-
gated in one arm of this study. Yet, we also identi-
fied a number of other, apparently less controversial,
studies. Some of these [45, 59, 70] had a higher
study quality and often larger patient samples than
remaining studies, indicating that their exclusion
may not be considered warranted. Studies of Ironson
et al. [62] and Resick et al. [68] were of comparably
lower quality, suggesting that their exclusion may be
considered warranted.
Excluding influential studies, exposure therapies and
prolonged exposure appeared more efficacious than
other treatments with regards to PTSD symptom se-
verity and recovery rates, whereas PCTs appeared
equally efficacious as other treatments with regards to
PTSD symptom severity. As the latter finding de-
pended on the exclusion of large and high-quality
studies [70, 71], we deem them likely biased. More-
over, systematic effects of study quality were also ob-
served in comparisons involving cognitive behavioural
therapy; differences at post-treatment and follow-up
were larger in studies with lower quality. Lastly, we
obtained evidence of publication bias, that, when ad-
justed for, revealed as its most significant result that
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PCTs were robustly less efficacious than other treat-
ments with regards to PTSD symptom severity.
Study quality appeared thus influential with regards
to aggregated tests of differential efficacy of bona fide
psychotherapies of PTSD. However, based on the
available evidence, obtained results appeared fickle
and need to be interpreted with caution. Even though
another seven studies over-and-above the 15 studies
investigated by Benish et al. [23] were identified and
included in the present meta-analysis, as much as nine
(41 %) of all included studies examined less than 20
patients within one or both treatment arms, and an-
other five (23 %) less than 30 patients; study quality
appeared, overall, only mediocre. In order to be able
to draw firmer conclusions, more high-quality studies
using ITT analyses are still needed in this field of research.
As the current debate on the relative efficacy of
PTSD treatments focused a lot on the topic of whether
individual studies should be included or excluded in
meta-analysis [29, 30], the sensitivity analyses reported
here show that this factor could actually be decisive in
terms of the overall meta-analytical result regarding
equal or different efficacy of compared treatments.
Concerning the consequences with regards to the dodo
bird verdict and the question of what works in psycho-
therapy, we thus recommend a refinement and clarifi-
cation of the bona fide definition which should ideally
result in a clear decision rule with regards to the inclu-
sion and exclusion of especially supportive and present-
centered therapies in analysis. Otherwise, the selection
of study samples may overly depend on the theoretical
position of the study authors, or meta-analyses from
authors with different theoretical positions might not
be adequately comparable.
Limitations
Using additional terms in the literature search, like the
names of specific psychotherapies (e.g., “CBT”, “exposure
therapy” or “EMDR”), might have provided additional stud-
ies that were overlooked using the present search terms.
Treatment categorizations adhered to the descriptions
provided in the studies themselves, which may have intro-
duced spurious heterogeneity with regards to categorization
and may have impacted on our results. Moreover, there
were too few studies for most of the specified treatment
types to systematically test effect moderation with moder-
ator analysis. Thus, effect size heterogeneity that could not
be traced to influential studies could mostly not be ex-
amined with regards to proposed moderator variables.
This affected specifically meta-analyses on EMDR, where
heterogeneity was substantial and could not be traced to
single influential studies.
The assessment of eligibiliy criteria, in particular the
bona fide status of treatments, is still a major point of
discussion. Hence, independent codings of a second
rater, in addition to comparing codings of the present
study with codings provided in other meta-analyses,
might have benefitted the reliability of our decisions to in-
clude or exclude studies in the present meta-analysis.
Studies were very variable with regards to time of
follow-up. Bradley et al. [13] suggested limiting compari-
sons at follow-up to assessments that took place six or
more months following end of treatment. In the present
study, all available follow-ups were used for analysis, re-
gardless of exact time of follow-up, which may have influ-
enced results. Specifically with regards to longer follow-up
periods results could be confounded, because patients
might have sought additional, external, treatment. This
needs to be controlled both in primary studies and meta-
analytical investigations. However, not enough informa-
tion was available in primary studies to investigate this
topic in the present meta-analysis.
Distinguishing different types of recovery and improve-
ment might accentuate differences in efficacy, particularly
because improvement is defined by study authors in dif-
ferent ways [13, 74]. As only nine studies reported re-
covery rates at post-treatment, combining recovery and
improvement rates allowed the assessment of clinical
significance, but may have influenced results.
Effects of researcher allegiance were neither examined
nor controlled for in the present study. Researcher alle-
giance may affect differences in treatment efficacy and
was reported to explain 12 % of variation in outcome re-
garding various trauma focused treatments [33]. How-
ever, allegiance failed to explain differences of efficacy in
a number of other meta-analyses [22, 27, 75], and it is
not clear whether allegiance ratings reliably reflect true
differences in allegiance [76] or how well meta-analytical
reviews may adjust for it.
Considering public health issues, a variety of topics
not considered here may still have to be evaluated
with regards to the comparative efficacy of treatments
[48]. Cost of treatments, the level of education and the
intensity of training of therapists, the preferences of
patients and the applicability of treatments for a wide
range of patients may influence what works best for
patients as well as what is affordable to implement in
public health care. For example, present-centered therapies
could be easier to deliver at a lower cost to more varied pa-
tients with a less skilled workforce, and these advantages
might compensate for a lower efficacy with regards to
health outcome. More research is needed here.
More research on traumatized populations with severe
comorbidities, like psychosis (mostly an exclusion criteria
in PTSD studies), as well as on patients with additional
and multiple life burdens and comorbidities, such as
homelessness, unemployment, suicidality or with a crimi-
nal justice involvement, is also needed [48]. Information
Tran and Gregor BMC Psychiatry  (2016) 16:266 Page 14 of 21
on the efficacy of PTSD treatments in such highly vulner-
able populations is currently lacking.
Conclusions
The bona fide distinction is an interesting and promising
research heuristic that is increasingly and independently
used in a number of meta-analyses [22, 27, 28], even
though its definition and criteria may need to be extended
or specified more clearly [10, 30]. The stated goal of the
present study was to apply this distinction, but not to
improve it. On these premises, evidence for at most small
differences in efficacy between bona fide psychotherapies
for PTSD was obtained. Differences were far below pro-
posed thresholds of clinically meaningful differences, but
corroborate that trauma focused treatments and prolonged
exposure and exposure therapies are slightly more effica-
cious than other therapies. While the lower efficacy of
present-centered therapies mirrors recent findings in the
field of treatment of depression, more high-quality research
is still needed to draw firm conclusions. Factors that may
affect and that may broaden the scope of treatment
efficacy, such as public health issues and the requirements
of highly vulnerable populations, are understudied in avail-
able research and need to be considered in future research.
Endnotes
1(a) Was the study described as randomized? (b)
Was the study described as double blind? (c) Was
there a description of withdrawals and dropouts? For
further information on the appropriate fulfillment of
each criteria and scoring, see [39].
2The study of Blanchard et al. [1] is of special inter-
est concerning the validity of the bona fide criteria for
the identification of active treatments. The authors
describe both treatments as active treatments giving
reasonable descriptions. Both treatments proved ef-
fective, but one of them did not mention the necessary
two of the four operational bona fide criteria (citation
of approach, reference to psychological process, treat-
ment manual, active ingredients with citation). This
study is therefore a good example as to why it may be
necessary to develop more valid operational criteria
(see Discussion).
3If a study presented comparisons between different
active treatments and between treatment components,
only the comparisons between the different active
treatments were included (see Table 1); comparisons
between treatment components were excluded. The
mentioned excluded studies contained only compari-
sons between treatment components.
Table 5 Primary outcome measures
# Studies Used in studies
Interviews
CAPS Clinician Administered PTSD Scale (Blake et al., 1995) 14 44–47, 58, 64, 66–73
PSS-I PTSD Symptom Scale (Foa, Riggs, Dancu, & Rothbaum, 1993) 2 42, 61
CGI Clinical Global Impression of PTSD (Guy, 1976) 1 46
PTSD-I PTSD Interview (Watson, Juba, Manifold, Kucala, & Anderson, 1991) 1 60
SI-PTSD Davidson’s Structured Interview for PTSD
(Davidson, Smith, & Kudler, 1989)
1 63
Self-report scales
IES/IES-R Impact of Events Scale (Horowitz, Wilner, & Alvarez, 1979) 9 45, 46, 57, 58, 60, 63,
66, 69, 72
PSS-SR PTSD Symptom Scale Self-Report (Foa et al., 1993) 5 60, 62, 66, 68, 69
PCL PTSD Checklist (Weathers, Litz, Herman, Huska, & Keane, 1993) 4 47, 59, 70, 71
CMS Civilian Mississippi Scale for PTSD (Keane, Caddell, & Taylor, 1988) 1 60
MMPI-K Keane’s Post-Traumatic Stress Disorder Scale from the Minnesota
Multiphasic Personality Inventory (Keane, Malloy, & Fairbank, 1984)
1 63
PENN Penn Inventory (Hammarberg, 1992) 1 72
PDS Post-traumatic Stress Diagnostic Scale (Foa, 1995) 1 65
SI-PTSD Davidson’s Structured Interview for PTSD, self-report version
(Davidson et al., 1989)
1 45
Appendix
Additionial Data and Results.
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Table 6 Secondary outcome measures
# Studies Used in studies
Measures of depression, anxiety, substance abuse, and of trauma-related guilt, anger, dissociation, and cognitions
BDI Beck Depression Inventory (Beck, Ward, Mendelsohn, Mock, & Erbaugh, 1961) 16 42, 44, 47, 58–63, 66–69, 71–73
HADS The Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) 1 45
HAM-D Hamilton Rating Scale for Depression (Hamilton, 1960) 1 66
MADRS Montgomery Asberg Depression Rating Scale (Montgomery & Asberg, 1979) 1 45
SRQ-20 Self-Reporting Questionnaire 20 (Harding et al., 1980) 1 65
STAI State-Trait Anxiety Inventory (Spielberger, Gorsuch, & Lushene, 1970) 9 42, 44, 57, 58, 60, 61, 66, 69, 71
HAM-A Hamilton Rating Scale for Anxiety (Hamilton, 1959) 3 45, 59, 66
BAI Beck Anxiety Inventory (Beck, Epstein, Brown, & Steer, 1988) 2 66, 72
FQ Fear Questionnaire (Marks & Mathews, 1979) 1 59
ASI Addiction Severity Index (McLellan et al., 1992) 1 71
SUI Substance Use Inventory (Sobell et al., 1980) 1 46
RAST Rape Aftermath Symptom Test (Kilpatrick, 1988) 1 42
NFQ Night Frequency Questionnaire (Krakow et al., 2000) 1 47
PSQI Pittsburgh Sleep Quality Index (Germain, Hall, Krakow, Shear, & Buysse, 2005) 1 47
NES Nightmare Effects Survey (Krakow et al., 1996) 1 47
TRGI Trauma-Related Guilt Inventory (Kubany et al., 1996) 1 68
COOK Cook-Medley Hostility Scale (Cook & Medley, 1954) 1 44
STAXI State-Trait Anger Expression Inventory (Spielberger, 1988) 2 44, 57
DES(−II) Dissociative Experiences Scale (Bernstein & Putnam, 1986) 2 44, 69
CCQ Catastrophic Cognitions Questionnaire (Khawaja & Oei, 1992) 1 58
WAS World Assumptions Scale (Janoff-Bulman, 1989) 1 66
Measures of quality of life, general symptom distress, and social functioning
QOLI Quality of Life Inventory (Frisch, Cornell, Villanueva, & Retzlaff, 1992) 3 44, 66, 71
QOLS Quality of Life Scale (Marks et al., 1993) 1 59
GHQ 28 General Health Questionnaire (Goldberg & Hillier, 1979) 2 70, 72
SF-36/12 Short-Form Health Survey (Ware & Sherbourne, 1992) 4 47, 65, 70, 71
SCL-90 (R) Symptom Checklist-90, Dutch version (Arindell & Ettema, 1981) 2 57, 60
SHEEHAN The Sheehan Disability Scale (Sheehan, 1986) 1 45
SAS Social Adjustment Scale (Weissman & Paykel, 1974) 1 61
Note. Listed are references to the original instruments, which may differ from references provided in the studies themselves
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Table 7 Treatment categorizations of included studies in the present meta-analysis compared to previous meta-analyses
Meta-analysis













Trauma desensitization EX (TF) – TFCBTa – EX – Brom et al. [57], p. 607: “The emphasis
of the hypnotherapists in our study was
on behavioral therapy. The goal was
to bring the patient in contact with the
reality of the traumatic event and to bring
about a decrease in the conditioned





– Otherb – Other –







– TFCBTa TFCBT CBT + EX In vivo exposure
or CBT
EMDR EMDR (TF) – EMDRa EMDR EMDR EMDR




– CBT – Inoculation training (Meichenbaum, 1974)
includes education, muscle relaxation
training, breathing retraining, role playing,
covert modeling, guided self-dialogue,
thought stopping (see Rothbaum
et al., 2000). No instructions for exposure
were included, see [42].
Prolonged exposure PE (TF) PE TFCBTa – EX –














Prolonged exposure PE (TF) PE TFCBTa – EX –





PE + SIT TFCBTa + SM – – –
Ironson et al.
[62]
EMDR EMDR (TF) – EMDRa EMDR EMDR –
Prolonged exposure PE (TF) – TFCBTa TFCBT EX –






TFCBT CBT + EX –
EMDR EMDR (TF) – EMDRa EMDR EMDR –
Marks et al.
[64]
Cognitive restructuring CBT (TF) Active
treatment
TFCBTa – CBT –































PE – – – – McDonagh et al. [44] investigated a
combination of exposure therapy
and cognitive restructuring
and consider their treatment as
CBT and as an extension of PE.
Cognitive elements are not
considered elements of prolonged
exposure, see [42].
Problem-solving therapy PCT Active
treatment





– TFCBTa – CBT + EX –







PE + CR TFCBTa TFCBT – –
EMDR EMDR (TF) Active
treatment
EMDRa EMDR – –
Resick et al.
[68]




TFCBTa – CBT + EX –
Prolonged exposure PE (TF) PE TFCBTa – EX –
Rothbaum
et al. [69]
EMDR EMDR (TF) Active
treatment
EMDRa EMDR – –







– Group TFCBTa – CBT + EX
Present-centered
group therapy




Present-centered therapy PCT Psych.
placebo
– – – –
Prolonged exposure PE (TF) PE – – – –
Tarrier
et al. [72]
Cognitive therapy CBT (TF) – TFCBTa – CBT –
Imaginal exposure EX (TF) – TFCBTa – EX –
Taylor
et al. [73]
EMDR EMDR (TF) Active
treatment
EMDRa EMDR EMDR – Taylor et al. [73] call one of their
treatments exposure therapy; this
treatment differs from prolonged
exposure, see [42]. Half of the
sessions were used for in vivo
exposition under supervision of
the therapists.
Exposure therapy EX (TF) PE TFCBTa TFCBT EX –







Note. Wait-list controls are not listed in this table. Bisson et al. [11], p. 103: a“Treatments delivered on an individual basis that focused on the memory for the traumatic event and its meaning.”/ b“Treatments delivered
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